• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy.

作者信息

Hwang Jessica P, Yilmaz Bulent

机构信息

Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

J Immunother Precis Oncol. 2020 Sep 29;4(2):53-55. doi: 10.36401/JIPO-20-19. eCollection 2021 May.

DOI:10.36401/JIPO-20-19
PMID:35663533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9153263/
Abstract
摘要

相似文献

1
Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy.接受免疫治疗的癌症患者中乙型肝炎病毒的再激活
J Immunother Precis Oncol. 2020 Sep 29;4(2):53-55. doi: 10.36401/JIPO-20-19. eCollection 2021 May.
2
Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.癌症治疗免疫疗法患者乙型肝炎病毒再激活的风险。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):898-907. doi: 10.1016/j.cgh.2021.06.019. Epub 2021 Jun 26.
3
Hepatitis B reactivation and immune check point inhibitors.乙型肝炎再激活与免疫检查点抑制剂
Dig Liver Dis. 2021 Apr;53(4):452-455. doi: 10.1016/j.dld.2020.08.041. Epub 2020 Sep 10.
4
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.癌症患者在接受 PD-1 抑制治疗时，若乙型肝炎表面抗原阳性，则可能会出现乙型肝炎病毒再激活。
J Immunother Cancer. 2019 Nov 21;7(1):322. doi: 10.1186/s40425-019-0808-5.
5
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.免疫检查点抑制剂治疗不可切除肝细胞癌患者的乙型肝炎病毒再激活风险。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-001072.
6
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.在免疫治疗时代重新考虑患有病毒性肝炎的癌症患者的管理。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000943.
7
Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan.台湾地区癌症患者乙型肝炎病毒再激活的真实世界患病率。
J Oncol Pharm Pract. 2021 Jan;27(1):63-70. doi: 10.1177/1078155220913095. Epub 2020 Apr 7.
8
Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.接受肿瘤坏死因子-α治疗的患者乙型肝炎病毒再激活的风险。
Int J Rheum Dis. 2021 Feb;24(2):254-259. doi: 10.1111/1756-185X.14034. Epub 2020 Nov 27.
9
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.乙型肝炎病毒在接受全身抗肿瘤治疗的实体瘤患者中的再激活。
Ann Oncol. 2016 Dec;27(12):2172-2184. doi: 10.1093/annonc/mdw414. Epub 2016 Nov 1.
10
[Immunotherapy with immune checkpoint inhibitors and hepatitis].[免疫检查点抑制剂免疫疗法与肝炎]
Rev Med Suisse. 2019 May 15;15(651):1017-1021.

引用本文的文献

1
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.免疫检查点抑制剂在癌症合并病毒性肝炎患者中的安全性和疗效：MD 安德森癌症中心的经验。
Oncologist. 2023 Aug 3;28(8):714-721. doi: 10.1093/oncolo/oyad039.
2
The immune system, cancer, and pathogens: It takes three to tango!免疫系统、癌症与病原体：三者共舞！
J Immunother Precis Oncol. 2021 May 14;4(2):33-34. doi: 10.36401/JIPO-21-X1. eCollection 2021 May.
3
Viral Infection and Lung Cancer Immunotherapy.病毒感染与肺癌免疫治疗
Front Oncol. 2021 Aug 9;11:577514. doi: 10.3389/fonc.2021.577514. eCollection 2021.
4
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy.乙型肝炎病毒感染状态与接受抗PD-1/PD-L1治疗的非小细胞肺癌患者结局的关联。
Transl Lung Cancer Res. 2021 Jul;10(7):3191-3202. doi: 10.21037/tlcr-21-455.

本文引用的文献

1
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.免疫检查点抑制剂在非小细胞肺癌合并乙型或丙型肝炎感染患者中的安全性和疗效。
Lung Cancer. 2020 Jul;145:181-185. doi: 10.1016/j.lungcan.2020.02.013. Epub 2020 Feb 24.
2
Management of hepatitis B in the era of checkpoint inhibition.在检查点抑制时代的乙型肝炎管理。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000276.
3
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.免疫检查点抑制剂（ICIs）在 HIV、乙型肝炎或丙型肝炎病毒感染的癌症患者中的安全性和疗效。
J Immunother Cancer. 2019 Dec 17;7(1):353. doi: 10.1186/s40425-019-0771-1.
4
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.癌症患者在接受 PD-1 抑制治疗时，若乙型肝炎表面抗原阳性，则可能会出现乙型肝炎病毒再激活。
J Immunother Cancer. 2019 Nov 21;7(1):322. doi: 10.1186/s40425-019-0808-5.
5
Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B.纳武单抗在一名肾细胞癌合并乙型肝炎患者中的安全使用。
J Oncol Pharm Pract. 2020 Jun;26(4):1022-1024. doi: 10.1177/1078155219882071. Epub 2019 Oct 21.
6
Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors' reply.信函：晚期肝细胞癌中程序性细胞死亡蛋白-1（PD-1）靶向免疫疗法：来自国际多中心真实世界队列的疗效和安全性数据——问题多于答案。作者回复
Aliment Pharmacol Ther. 2019 Jul;50(2):231-232. doi: 10.1111/apt.15334.
7
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.免疫检查点抑制剂的不良反应：流行病学、管理和监测。
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.
8
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.程序性死亡受体 1（PD-1）靶向免疫疗法治疗晚期肝细胞癌：来自国际多中心真实世界队列的疗效和安全性数据。
Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.
9
A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B.帕博利珠单抗诱发乙型肝炎再激活的罕见病例。
Case Rep Oncol Med. 2018 Oct 17;2018:5985131. doi: 10.1155/2018/5985131. eCollection 2018.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.